Schering-Plough Intron/Rebetron
Executive Summary
Combined sales of Intron A (interferon alfa-2b) and Rebetron (interferon/ribavirin) increased 66% for the quarter to $272 mil., Schering reported. In the U.S., sales of the interferon franchise nearly doubled (up 94%), helped by the introduction of Rebetron in 1998. The interferon line is now half as large in terms of sales as Schering's flagship antihistamine Claritin (up 29% for the quarter to $565 mil.)